The four drugs that are currently available for the treatment of acute angioedema attacks (purified plasma-derived human C1 esterase inhibitor concentrate, icatibant acetate, ecallantide, and recombinant human C1 esterase inhibitor) are all authorized for self-administration, except ecallantide [12]. The gene discussed is C1S; the disease is angioedema.